1-9 of 9
Keywords: Multi-infarct dementia
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Neuropsychobiology (1996) 34 (1): 29–35.
Published Online: 26 February 2008
... or the multi-infarct dementia (MID) group was based on computed tomography scans, electroencephalographic findings and the Hachinski Ischemic Score. In a 12-week double-blind treatment either 30 mg vincamine or placebo was given twice daily. Confirmatory statistics included item 2 of the Clinical Global...
Journal Articles
Journal Articles
Neuropsychobiology (1992) 25 (4): 188–192.
Published Online: 21 February 2008
...E. Rolandi; C. Gandolfo; R. Franceschini; A. Cataldi; A. Garibaldi; T. Barreca A chronobiological study was carried out in 6 male patients (67–71 years), suffering from Alzheimer-type dementia (ATD) and 6 male patients (52–74 years) suffering from multi-infarct dementia (MID), to evaluate their 24...
Journal Articles
Journal Articles
Neuropsychobiology (1989) 21 (3): 141–145.
Published Online: 20 February 2008
... significant changes were observed on routine laboratory examinations. Neuropsychobiology 1989;21:141-145 © 1989 S. Karger AG, Basel 0302-282X/89/0213 -0 141 $2.75/0 Oxiracetam in the Treatment of Primary Degenerative and Multi-Infarct Dementia: A Double-Blind, Placebo-Controlled Study G. Mainaa, L. Fiori*, R...
Journal Articles
Neuropsychobiology (1982) 8 (2): 109–112.
Published Online: 19 February 2008
...T.K. Sluss; E.M. Gruenberg; P. Rabins; M. Kramer The distribution of signs indicative of localized brain damage important in the diagnosis of multi-infarct dementia (MID) has not been specified. The demented members of a longitudinally examined research panel (n = 519) were identified. Differential...
Journal Articles
Journal Articles
Journal Articles
Neuropsychobiology (1992) 25 (1): 24–28.
Published Online: 01 January 1992
...C. Villardita; S. Grioli; C. Lomeo; C. Cattaneo; J. Parini The cognitive and behavioral effects and the safety of oxiracetam therapy during a placebo-controlled trial and the relevant follow-up up to 1 year in patients with senile dementia of Alzheimer type (SDAT) and multi-infarct dementia (MID...